Ultragenyx Pharmaceutical(US:RARE) TMX Newsfile·2026-02-08 19:46Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ultragenyx Pharmaceutical Inc due to allegations of violations of federal securities laws related to misleading statements about the effects of setrusumab on patients with Osteogenesis Imperfecta [4]. Group 1: Legal Investigation - The law firm is encouraging Ultragenyx investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Ultragenyx, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Ultragenyx - The complaint alleges that Ultragenyx and its executives created a false impression regarding the reliability of information on setrusumab's effects, while downplaying the risks associated with the Phase III Orbit study [4]. - It is claimed that Ultragenyx's optimism regarding the study's results was misplaced, as the data was based on Phase II results without a placebo control group, raising concerns about the validity of the findings [4]. Group 3: Participation and Whistleblower Information - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [5]. - The firm is also encouraging individuals with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to come forward [6].